News | March 10, 2015

Acute Myocardial Infarction Patient Treated with New Mechanical Thrombectomy Device

Aspire system removes thrombus occluding blood vessel in coronary arteries

Aspire, Control Medical, thrombectomy, atherectomy devices, cath lab

March 10, 2015 —George Adams, M.D., an interventional cardiologist with North Carolina Heart and Vascular, successfully treated a patient having an acute myocardial infarction (AMI) with the Aspire Mechanical Thrombectomy System.

The patient presented with chest pain, nausea and shortness of breath. An angiogram was performed and showed a long segment of thrombus occluding the ramus intermedius, a blood vessel in the coronary arteries. Adams used the Aspire Mechanical Thrombectomy device to remove the thrombus, and then he was able to angioplasty and stent the artery, relieving the patient from his symptoms.

"When a patient is having an AMI, removing the thrombus in the symptomatic artery is important," said Adams. "The Aspire device allows me to remove the thrombus quickly, helping to relieve the patients symptoms."

The Aspire System allows clinicians to instantly start, stop, increase, decrease, pulse or maintain thrombectomy force during the procedure. Aspire Mechanical Aspirators also aspirate up to 280ml, almost 10 times more than basic syringe systems, without multiple messy and time-consuming catheter connections, disconnections and re-connections.

The patented Aspire RX-LP6 Mechanical Thrombectomy System includes an Aspire Mechanical Aspirator (drive unit/pump) and a low-profile rapid-exchange (RX) thrombectomy catheter. Mechanical aspirators are also available alone and may be connected to any thrombectomy catheter the clinician chooses to use. Control Medical also manufactures Aspire Max Mechanical Thrombectomy Systems with larger over-the-wire (OTW) thrombectomy catheters for use in the peripheral vasculature.

For more information:

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init